3 results
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Approved WMOCompleted
To evaluate the efficacy (superiority) and safety of BAY 41-6551 as measured by the comparison of the clinical cure rate of aerosolized BAY 41-6551, administered via the PDDS Clinical, versus placebo (normal saline) at the Test-of-Cure (TOC0 visit…
Approved WMOPending
To prospectively assess the potential effect of repeated exposure to either a linear or amacrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 inmotor and cognitive function among neurologically normal adults in…